NasdaqHealth CareHealth Care FacilitiesS&P MidCap 400
$31.65
+0.15 (+0.48%)
Close of Nov 06, 2026 · end-of-day data
OPCH 8-K filings in 2025
Every material Form 8-K Option Care Health filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Option Care Health reported third quarter 2025 net revenue of $1,435.0 million, up 12.2%, and GAAP diluted EPS of $0.32, up 3.2%, while net income fell 3.8% to $51.8 million. The company also updated its full-year 2025 guidance, now expecting net revenue of $5.60 billion to $5.65 billion and adjusted diluted EPS of $1.68 to $1.72.
Q3 net revenue $1,435.0 million, up 12.2%; net income $51.8 million, down 3.8%
GAAP diluted EPS $0.32, up 3.2%; adjusted diluted EPS $0.45, up 9.8%
Full-year 2025 guidance: net revenue $5.60 billion to $5.65 billion; adjusted diluted EPS $1.68 to $1.72
Option Care Health entered a Fourth Amendment to its first lien credit agreement with Bank of America, N.A. as administrative agent, dated September 22, 2025. The amendment refinances existing term loans at a lower rate of Term SOFR plus 1.75% with a seven-year maturity, adds $49,639,386.20 in incremental term loans, and extends the revolving credit maturity to five years.
Term loans refinanced at Term SOFR plus 1.75%, maturing seven years after the amendment's effective date
Incremental term loans of $49,639,386.20 added on the same rate and maturity terms
Post-amendment First Lien Term Loan principal is approximately $678,000,000
Revolving credit commitments extended to the fifth anniversary, with a springing maturity 91 days before the Unsecured Notes maturity if notes remain unpaid
Option Care Health said Meenal Sethna, most recently Executive Vice President and Chief Financial Officer of Littelfuse, will become its Executive Vice President and Chief Financial Officer effective October 1, 2025. She succeeds Michael Shapiro, who steps down as CFO effective September 30, 2025 after ten years and will stay on as a non-executive Strategic Advisor, with the 8-K citing service through March 31, 2026.
Meenal Sethna becomes EVP and CFO effective October 1, 2025; Michael Shapiro steps down as CFO effective September 30, 2025.
Sethna's initial pay includes a $655,000 base salary, a 90% target cash incentive and $2,400,000 annual target long-term incentive compensation.
Sethna receives a restricted stock unit award with a $1,500,000 grant date fair value that vests on the third anniversary of her employment start.
Shapiro's base salary will fall from $615,000 to $246,000 under a transition agreement.
Option Care Health reported second quarter 2025 results on July 30, 2025, with net revenue of $1.42 billion, up 15.4% from a year earlier, and adjusted diluted EPS of $0.41, up 10.8%. GAAP net income slipped to $50.5 million from $53.0 million, while operating cash flow fell to $90.3 million from $195.7 million, and the company updated its full-year 2025 guidance.
Q2 net revenue $1,416.1 million, up 15.4% from $1,227.2 million; gross margin 19.0% versus 20.3% a year earlier
Diluted EPS $0.31 versus $0.30; net income $50.5 million versus $53.0 million; adjusted diluted EPS $0.41 versus $0.37
Operating cash flow $90.3 million versus $195.7 million in Q2 2024; about $50.0 million of stock repurchased in the quarter
Updated 2025 guidance: net revenue $5.50 billion to $5.65 billion, adjusted diluted EPS $1.65 to $1.72, adjusted EBITDA $465 million to $475 million
Option Care Health reported first quarter 2025 net revenue of $1.33 billion, up 16.3% from a year earlier, and diluted earnings per share of $0.28, up from $0.26. The company also updated its full year 2025 guidance, which now calls for net revenue of $5.4 billion to $5.6 billion and adjusted diluted EPS of $1.61 to $1.70, but the filing does not say whether this is higher or lower than prior guidance.
Net revenue $1.33 billion vs. $1.15 billion in Q1 2024; gross margin fell to 19.7% from 20.8%
Net income $46.7 million vs. $44.8 million; adjusted diluted EPS $0.40 vs. $0.35
Cash used in operating activities $7.2 million vs. $68.8 million; company repurchased about $100.0 million of stock
2025 guidance: adjusted EBITDA $455 million to $470 million and cash flow from operations of at least $320 million
Option Care Health reported fourth quarter and full-year 2024 results on February 26, 2025, with net revenue and adjusted earnings per share both higher than in 2023. GAAP diluted earnings per share fell 16.9% for the full year, which the company tied to non-operating income in 2023. The company also issued 2025 guidance calling for net revenue of $5.3 billion to $5.5 billion and adjusted diluted earnings per share of $1.59 to $1.69.
Q4 2024 net revenue was $1,346.4 million, up 19.7% from $1,124.4 million; GAAP diluted EPS was $0.35, up 9.4%.
Q4 2024 adjusted diluted EPS was $0.44, up 15.8% from $0.38; company repurchased approximately $90.0 million of stock in the quarter.
Full-year 2024 net revenue was $4,998.2 million, up 16.2%; GAAP diluted EPS was $1.23, down 16.9%; adjusted diluted EPS was $1.58, up 10.5%.
2025 guidance: net revenue of $5.3 billion to $5.5 billion and adjusted diluted EPS of $1.59 to $1.69; cash flow from operations of at least $320 million.
Option Care Health reported preliminary, unaudited fourth-quarter and full-year 2024 results, with full-year net revenue of about $4.99 billion to $5.00 billion, up 16.0% to 16.2%, and adjusted diluted EPS of $1.55 to $1.59. For 2025 it expects net revenue of $5.2 billion to $5.4 billion and adjusted EPS of $1.59 to $1.69, including a $60 million to $70 million gross profit reduction tied to Stelara pricing adjustments. The Board also approved a new $500 million share repurchase program with no specified expiration date.
Q4 2024 net revenue of about $1.34 billion to $1.35 billion, up 19.2% to 20.1% year over year
Full-year 2024 adjusted diluted EPS of $1.55 to $1.59; GAAP diluted EPS of $1.21 to $1.23
2025 guidance: net revenue of $5.2 billion to $5.4 billion and adjusted EBITDA of $445 million to $465 million
New $500 million share repurchase program approved January 10, 2025; full results due February 26, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Option Care Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →